Which patients suit each pathway

The eligibility question comes before cost or recovery — and both pathways share the same narrow entry criteria. A candidate for either the ChondroFiller injection or arthroscopic cartilage repair needs a focal, contained defect: an area of cartilage loss with structurally sound tissue at its borders and a joint that has not yet progressed to diffuse or end-stage osteoarthritis. Neither pathway is appropriate for bone-on-bone disease.

Within that shared starting point, the details diverge. ChondroFiller injection is indicated for defects up to approximately 6 cm², treated across one, two, or three compartments (corresponding to the one-, two-, and three-box dosing tiers). In Mazek 2021's prospective cohort of hip patients, those with pre-existing Tönnis grade 2–3 osteoarthritis fared poorly — confirming that OA grade, not defect size alone, governs eligibility. One practical advantage of the injection route is joint range: it covers the knee, hip, ankle, shoulder, and further joints, whereas the published arthroscopic repair evidence base is weighted heavily towards the knee.

ACI, the most evidence-rich surgical option, carries an overall long-term success rate of around 82%, but that figure is sensitive to biology and anatomy: outcomes decline significantly for defects above 4.5 cm² and in older patients at the time of procedure.

Patients whose imaging reveals early osteoarthritic change throughout the joint — rather than a well-bordered, isolated lesion — are unlikely to be offered either pathway. Setting that expectation clearly at the point of assessment avoids disappointment and directs the clinical conversation towards the options that genuinely remain open.

What happens on the day

Once eligibility is confirmed, the practical experience of each pathway diverges substantially — and for many patients, that difference is as significant as the clinical one.

A ChondroFiller injection appointment typically takes 30 to 45 minutes. There is no general anaesthetic, no theatre booking, and no surgical portals. Under real-time ultrasound guidance, the injectable collagen scaffold is placed directly into the defect, where it gels in situ at body temperature within a few minutes. From that point it acts as an instructive matrix for acellular matrix-induced chondrogenesis — recruiting the patient's own progenitor cells from the surrounding synovium to support repair. Patients are discharged the same day.

Arthroscopic cartilage repair occupies a different register entirely. Even a straightforward chondroplasty or debridement requires a theatre slot, an anaesthetist, surgical instruments, and a formal recovery plan. Microfracture and scaffold-assisted repair add complexity and post-operative restrictions. ACI, which NICE approved under TA477, is structured across two distinct stages in many protocols — an initial biopsy harvest followed, weeks later, by a separate implantation procedure under anaesthesia.

For patients with cardiovascular comorbidities, reduced anaesthetic tolerance, or a strong preference for avoiding theatre, the absence of both general anaesthetic and wound-healing demands in the injection pathway is a clinically meaningful distinction rather than a minor convenience.

Recovery timelines side by side

Recovery looks very different depending on which pathway a patient takes — and for those fitting work, family, and rehabilitation around an active life, the gap matters.

Following a ChondroFiller injection, most patients can resume light daily activity within days and return home the same afternoon. The scaffold continues remodelling over subsequent weeks and months; that biological timeline runs independently of how quickly mobility returns. Physiotherapy is not included in the injection package and should be planned and budgeted separately — the recovery burden is lower, but it is patient-paced rather than protocol-driven.

For arthroscopic procedures, timelines lengthen appreciably with procedural complexity:

• Simple chondroplasty or debridement: approximately 6 weeks to return to normal daily activities.
• Microfracture: partial non-weight-bearing for up to 6 weeks post-operatively; return to light sport at roughly 4–6 months; full sport typically 6–9 months.
• ACI: the most demanding recovery of any cartilage repair option — 9–12 months of structured rehabilitation as a minimum, with physiotherapy follow-up that may extend to 18 months.

For a patient who cannot take extended leave or who manages responsibilities that require reliable mobility within weeks rather than months, the difference between an outpatient afternoon and a nine-to-twelve-month supervised rehabilitation programme is a practical factor worth weighing alongside the clinical one.

What the clinical evidence shows

The evidence base for cartilage regeneration varies considerably in quality and volume depending on technique — and understanding those differences matters when weighing options.

For the ChondroFiller injection pathway, clinic-reported data point to roughly a 30-point improvement on IKDC scores for knee defects, with MOCART cartilage fill scores in the range of 70–87. These are observational figures from clinical practice rather than randomised trial data, and the injection-route evidence is shorter-term than the surgical literature surrounding it.

The most cited peer-reviewed study specific to ChondroFiller is Mazek 2021 (n=26), which examined arthroscopic delivery in the hip — not the current outpatient injection pathway, and therefore best read as biological context rather than direct service evidence. Of 21 evaluable patients followed over three to five years, 17 achieved good or excellent outcomes. Crucially, patients with pre-existing Tönnis grade 2–3 osteoarthritis fared poorly — reinforcing that ChondroFiller, like its surgical counterparts, is a focal-defect treatment rather than a remedy for advanced joint disease.

ACI carries the most established evidence base among the surgical alternatives: an overall long-term success rate of approximately 82%, though this declines meaningfully when defects exceed 4.5 cm² or when patients are older at the time of procedure.

On tissue quality, the distinction between microfracture and scaffold-mediated approaches is mechanically significant. Microfracture stimulates fibrocartilage — a repair tissue softer and less durable than native hyaline cartilage. A 2025 comparative study found microdrilling outperformed microfracture on MOCART 2.0 cartilage fill and IKDC subjective scores in distal femoral lesions, suggesting that even within marrow-stimulation techniques, method matters. ChondroFiller's collagen matrix supports acellular matrix-induced chondrogenesis, with proponents reporting hyaline-like repair tissue as a result — a genuine mechanistic distinction, not a marketing one.

No published head-to-head RCT directly compares the ChondroFiller injection pathway against arthroscopic cartilage repair on patient-reported outcomes or UK cost-effectiveness. That gap is worth stating plainly; it applies across most emerging regenerative options and should inform how carefully patients discuss their individual circumstances with a specialist.

Private costs and NHS access in the UK

Putting figures side by side requires care, because headline prices rarely cover the same things.

ChondroFiller injection guide costs

The ChondroFiller injection is privately funded — there is currently no NHS commissioning pathway and no NICE health technology appraisal for this product. Guide costs at the London Cartilage Clinic follow a tiered box model based on defect area:

• One box (~3 cm²): £3,000
• Two boxes (~4.5 cm²): £5,500
• Three boxes (~6 cm²): £8,000
• Complex or multi-compartment cases: up to £9,800

Each tier is all-inclusive: consultation, real-time ultrasound guidance, the scaffold itself, IV antibiotic cover, and a six-week follow-up review are all within the quoted figure. Post-procedure physiotherapy is not bundled and should be budgeted separately.

Private arthroscopic cartilage surgery guide costs

Private knee arthroscopy averaged approximately £4,492 in October 2024 data, with Spire Healthcare listing treatment from £4,230 plus a £225 initial consultation. That baseline figure applies to standard chondroplasty or debridement; arthroscopic cartilage repair with scaffold support starts at around £9,800 at specialist centres for the knee. ACI — which requires two operative stages and laboratory cell culture — is estimated at approximately £16,000 per patient. The full private cartilage regeneration spectrum extends to £28,000 for single-stage implantation procedures. Post-operative physiotherapy is typically an additional cost for surgical pathways too.

NHS access

For patients exploring an NHS route, standard arthroscopic procedures are available without charge, though waiting lists currently average 15–30 weeks. ACI was approved by NICE under TA477 in 2017 and remains the only cartilage cell therapy commissioned by the NHS; eligible patients should discuss a referral with their GP. Private surgery, by contrast, can generally be scheduled within 2–6 weeks.

For smaller focal defects, the ChondroFiller injection price range and the entry-level private arthroscopy range overlap; injection is not automatically the cheaper option. The more meaningful cost differences emerge at the complex end — multi-compartment injection cases and scaffold-assisted or two-stage surgical repair — where the gap widens substantially. All figures should be confirmed directly with the treating clinic, as costs vary with defect complexity, joint, and provider.

Getting an assessment at London Cartilage Clinic

Deciding between an outpatient injection and a surgical pathway depends on defect size, OA grade, joint involvement, and personal circumstances — factors only imaging and a clinical assessment can weigh accurately for a given patient. For a small, well-bordered focal defect where anaesthetic avoidance or recovery time is a genuine priority, the ChondroFiller injection pathway is often worth exploring first. For larger defects, significant OA burden, or cases where the depth of the ACI evidence base is the preferred benchmark, surgery is likely the stronger recommendation — and a thorough assessment will say so clearly rather than default to the injection route.

The ChondroFiller injection is delivered at the London Cartilage Clinic on Harley Street, the UK certified delivery centre for the Liquid Cartilage™ service. Professor Paul Y. F. Lee leads the service; precise ultrasound-guided placement of the collagen scaffold is a technique-sensitive step, and how well the matrix integrates is influenced in part by the accuracy of positioning. An initial consultation reviews imaging, defect characteristics, OA grade, and individual patient factors before any pathway is recommended — the outcome of that conversation may equally be a referral for surgical assessment.

Assessments are booked at londoncartilage.com.